Sources

13 Total Sources

Sellas' GPS Leukemia Vaccine Cuts Death Risk 41% in 126-Patient Phase 3 Trial

The Washington Post1h ago
Sellas' Leukemia Vaccine GPS Succeeds Phase 3 Trial, Reduces Death Risk 41%
BioSpace9h ago
Sellas' cancer vaccine slashes death risk by 41% in late-stage AML study - BioSpace
Yahoo Finance7h ago
Sellas Life Sciences shares surge 175% after cancer vaccine succeeds in late-stage trial
Bloomberg1h ago
Sellas Life Sciences Stock Triples After Late-Stage Cancer Vaccine Data - Bloomberg
nacionale.com1h ago
Sellas GPS: 41% lower death risk in Phase 3 AML trial
StockTitan1h ago
SELLAS REGAL Phase 3 trial cuts AML death risk 41% | SLS Stock News
The Globe and Mail1h ago
SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients... - The
Quartz1h ago
Sellas stock soars as much as 233% on leukemia vaccine trial data
GlobeNewswire1h ago
SELLAS Life Sciences Announces Positive Pivotal Phase 3
Coinpedia Fintech News7h ago
SLS Stock Soars More Than 200% After Phase 3 Cancer Vaccine Success: What's Next for SELLAS Life Sciences?
X10h ago
Wall St Engine on X: "$SLS +300% (Market cap: ~$6B) Sellas Life Sciences' experimental cancer vaccine extended survival in a pivotal Phase 3 leukemia trial, meeting its primary endpoint. Its vaccine, galinpepimut-S (
TradingView12h ago
Sellas' GPS Cuts Death Risk By 41% In Pivotal AML Trial – Firm Eyes FDA Filing In First Half Of 2027 — TradingView News
Minichart1d ago
SELLAS Phase 3 REGAL Hits Survival Endpoint; GPS Cuts Death Risk 41% in AML – Minichart